Brokerages Set Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Target Price at $31.00

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been given an average recommendation of “Hold” by the five brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $31.00.

Several equities analysts have recently weighed in on ETON shares. Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th.

Institutional Trading of Eton Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ETON. Divisadero Street Capital Management LP acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth $7,092,000. Geode Capital Management LLC boosted its position in shares of Eton Pharmaceuticals by 98.8% during the 2nd quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock valued at $8,450,000 after acquiring an additional 294,617 shares during the last quarter. Soleus Capital Management L.P. acquired a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $4,061,000. Millennium Management LLC grew its holdings in shares of Eton Pharmaceuticals by 156.3% in the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares during the period. Finally, Oberweis Asset Management Inc. purchased a new stake in shares of Eton Pharmaceuticals in the third quarter valued at about $4,180,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Trading Up 5.1%

Shares of ETON opened at $19.02 on Friday. Eton Pharmaceuticals has a 52-week low of $11.09 and a 52-week high of $23.00. The stock has a market cap of $510.12 million, a PE ratio of -76.08 and a beta of 1.19. The firm’s fifty day moving average is $16.31 and its two-hundred day moving average is $17.27. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.